Literature DB >> 18181565

Multi-target-directed ligands to combat neurodegenerative diseases.

Andrea Cavalli1, Maria Laura Bolognesi, Anna Minarini, Michela Rosini, Vincenzo Tumiatti, Maurizio Recanatini, Carlo Melchiorre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18181565     DOI： 10.1021/jm7009364

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  187 in total

Review 1.  Metals, oxidative stress and neurodegenerative disorders.

Authors:  Klaudia Jomova; Dagmar Vondrakova; Michael Lawson; Marian Valko
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

2.  Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.

Authors:  Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurochem Res       Date:  2010-10-28       Impact factor: 3.996

Review 3.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

4.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

5.  Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment.

Authors:  Cédric Lecoutey; Damien Hedou; Thomas Freret; Patrizia Giannoni; Florence Gaven; Marc Since; Valentine Bouet; Céline Ballandonne; Sophie Corvaisier; Aurélie Malzert Fréon; Serge Mignani; Thierry Cresteil; Michel Boulouard; Sylvie Claeysen; Christophe Rochais; Patrick Dallemagne
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

6.  Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol.

Authors:  Catherine A S Deane; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2016-06-08       Impact factor: 3.667

Review 7.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

8.  Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.

Authors:  Jie Gao; Bao-Ling Adam; Alvin V Terry
Journal:  Bioorg Med Chem Lett       Date:  2014-02-14       Impact factor: 2.823

9.  Celastrol from 'Thunder God Vine' protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson's disease.

Authors:  Bong-Suk Choi; Hyool Kim; Hyo Jeong Lee; Kumar Sapkota; Se Eun Park; Seung Kim; Sung-Jun Kim
Journal:  Neurochem Res       Date:  2013-11-09       Impact factor: 3.996

10.  sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-β in Alzheimer's disease.

Authors:  Anthony J Veloso; Devjani Dhar; Ari M Chow; Biao Zhang; Derek W F Tang; Hashwin V S Ganesh; Svetlana Mikhaylichenko; Ian R Brown; Kagan Kerman
Journal:  ACS Chem Neurosci       Date:  2012-11-20       Impact factor: 4.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.